GeneGo and Omicsoft Collaborate on Pathway Analysis for Next Generation Sequence Data
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
GeneGo, Inc., and Omicsoft Corporation announced have integration of Omicsoft's Next Generation Sequencing tools with GeneGo's MetaCore data mining suite.
Array Studio, Omicsoft's software package that provides statistics analysis and visualization tools for high dimensional quantification data (OMICS data), also supports analysis of Next Generation Sequencing Data (both RNA-Seq and DNA-Seq).
Omicsoft has developed high performance proprietary sequence alignment algorithms for the major NGS platforms, i.e. Illumina's Solexa, Roche's 454 and SOLID from Life Technologies. Array Studio fully supports known and novel exon junction detection, fusion gene detection (both single end and paired end), expression value calculation, along with mutation reporting/annotation and more, all in one software package which can provide complete analysis from machine-generated sequence runs to the lists of modified genes and polymorphisms.
Array Studio is integrated with GeneGo's data mining suites MetaCore and MetaDrug, allowing in depth analysis of the users NGS data.
"Omicsoft is delighted to continue its partnership with GeneGo, as the –OMICs field enters a new era with next generation sequencing technology. We feel that our alignment algorithm, coupled with our industry leading visualization and statistical package Array Studio, will allow us to continue to pave the way in the –OMICs industry. The extra benefits provided by NGS platforms, for instance, detection of gene fusion, will play a key role in biomarker discovery in cancer genomics. Integration with GeneGo's platforms is key to this success, through their tools for systems biology," said Jack Liu, President of Omicsoft.
"We are happy to extend our long-term collaboration with Omicsoft into next-generation sequencing," said Julie Bryant, GeneGo's VP of Business development. "NGS technologies provide the richest content data in life sciences, and we believe that they have one of the most comprehensive solutions. Pathway and network analysis is a natural next step for these complex data, and we are glad that we can provide our customers with a seamlessly integrated workflows from raw sequence data to biologically meaningful hypotheses on biomarkers, drug targets and drug repositioning."
Array Studio, Omicsoft's software package that provides statistics analysis and visualization tools for high dimensional quantification data (OMICS data), also supports analysis of Next Generation Sequencing Data (both RNA-Seq and DNA-Seq).
Omicsoft has developed high performance proprietary sequence alignment algorithms for the major NGS platforms, i.e. Illumina's Solexa, Roche's 454 and SOLID from Life Technologies. Array Studio fully supports known and novel exon junction detection, fusion gene detection (both single end and paired end), expression value calculation, along with mutation reporting/annotation and more, all in one software package which can provide complete analysis from machine-generated sequence runs to the lists of modified genes and polymorphisms.
Array Studio is integrated with GeneGo's data mining suites MetaCore and MetaDrug, allowing in depth analysis of the users NGS data.
"Omicsoft is delighted to continue its partnership with GeneGo, as the –OMICs field enters a new era with next generation sequencing technology. We feel that our alignment algorithm, coupled with our industry leading visualization and statistical package Array Studio, will allow us to continue to pave the way in the –OMICs industry. The extra benefits provided by NGS platforms, for instance, detection of gene fusion, will play a key role in biomarker discovery in cancer genomics. Integration with GeneGo's platforms is key to this success, through their tools for systems biology," said Jack Liu, President of Omicsoft.
"We are happy to extend our long-term collaboration with Omicsoft into next-generation sequencing," said Julie Bryant, GeneGo's VP of Business development. "NGS technologies provide the richest content data in life sciences, and we believe that they have one of the most comprehensive solutions. Pathway and network analysis is a natural next step for these complex data, and we are glad that we can provide our customers with a seamlessly integrated workflows from raw sequence data to biologically meaningful hypotheses on biomarkers, drug targets and drug repositioning."
